Taysha Gene Therapies’ (TSHA) Buy Rating Reaffirmed at Chardan Capital

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $7.00 target price on the stock. Chardan Capital’s price target suggests a potential upside of 332.10% from the company’s previous close.

TSHA has been the topic of several other reports. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Canaccord Genuity Group raised their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, January 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies presently has an average rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Stock Down 4.7 %

Shares of TSHA traded down $0.08 during midday trading on Wednesday, hitting $1.62. The company had a trading volume of 2,118,480 shares, compared to its average volume of 2,111,894. The stock has a market cap of $332.01 million, a price-to-earnings ratio of 2.57 and a beta of 0.93. The company’s 50 day moving average price is $1.69 and its 200 day moving average price is $1.99. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. On average, equities research analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current year.

Institutional Trading of Taysha Gene Therapies

Several hedge funds have recently bought and sold shares of TSHA. Octagon Capital Advisors LP grew its position in Taysha Gene Therapies by 128.6% in the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company’s stock worth $18,078,000 after purchasing an additional 5,877,778 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of Taysha Gene Therapies during the fourth quarter worth approximately $8,650,000. Bank of America Corp DE grew its holdings in Taysha Gene Therapies by 1,178.9% in the 4th quarter. Bank of America Corp DE now owns 1,710,303 shares of the company’s stock worth $2,959,000 after buying an additional 1,576,568 shares in the last quarter. Norges Bank acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at approximately $2,528,000. Finally, Avoro Capital Advisors LLC raised its stake in Taysha Gene Therapies by 7.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company’s stock valued at $34,600,000 after acquiring an additional 1,349,999 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.